Fumaric Acid Ester Stability via Controlled Photodimer Formation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Fumaric acid esters, particularly (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, are prone to photodegradation and oxidative stress, leading to the formation of undesirable impurities when exposed to light or oxidants.
Innovation Solution
A pharmaceutical dosage form comprising a therapeutically effective amount of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, along with specific cyclobutane compounds and a pharmaceutically acceptable vehicle, is designed to minimize the presence of photodegradant compounds, thereby maintaining stability and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fumaric acid esters are exposed to light or oxidants, then photodegradation and oxidative stress occur leading to formation of undesirable impurities, but the therapeutic effectiveness and stability are compromised
Solution Approach 1:
The patent converts the harmful photodegradation reaction into a beneficial outcome by controlling the formation of photodimers. The cyclobutane compounds (photodimers) that would normally be considered degradation products are instead controlled to be present at specific low levels (0.01-5% by HPLC area percent), transforming the harmful photodegradation pathway into a controlled process that maintains product stability and efficacy while meeting regulatory requirements.
Solution Approach 2:
The patent establishes specific parameter ranges for photodimer content (0.01-5% by HPLC area percent) and controls synthesis conditions (reactants, catalysts, temperature, time) to optimize the balance between maintaining therapeutic effectiveness and minimizing harmful impurities. This parameter control transforms the uncontrolled photodegradation into a managed process.
2Reliability
If strict control of photodegradant compound levels is implemented, then stability and therapeutic effectiveness are enhanced, but manufacturing complexity and analytical detection requirements increase
Solution Approach 1:
The patent performs preliminary control during the synthesis stage by selecting specific reaction conditions, catalysts, and purification methods that prevent excessive formation of photodimer impurities before they become problematic. This preliminary action simplifies downstream processing and reduces the complexity of final product control by addressing impurity formation at the source.
Solution Approach 2:
The patent replaces complex mechanical separation systems with chemical control strategies. By controlling the synthesis conditions and using selective purification methods, the patent achieves impurity control without requiring complex multi-stage separation equipment, thereby reducing manufacturing complexity while maintaining effectiveness.
3Stability of the object's composition
If photostabilizers are incorporated into formulations, then photostability is improved to some extent, but additional ingredients and formulation complexity are introduced
Solution Approach 1:
The patent employs the fumaric acid ester compound itself to provide photostability through controlled photodimer formation. The compound's own photochemical properties are harnessed to protect against degradation, eliminating the need for separate photostabilizer additives. This self-service approach maintains photostability while avoiding the complexity of additional formulation ingredients.
Solution Approach 2:
The controlled photodimer compounds act as intermediaries that mediate the photodegradation process. Instead of using external photostabilizers, the patent allows controlled formation of these intermediate photodimer products that actually protect the main active ingredient from further degradation, simplifying the formulation while maintaining stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dosage form effectively reduces the levels of photodegradant compounds, enhancing the stability and therapeutic effectiveness of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, while ensuring safety and compliance with regulatory standards.
Implementation Method 1
Fumaric acid esters, particularly (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, are prone to photodegradation and oxidative stress, leading to the formation of undesirable impurities when exposed to light or oxidants.
Implementation Method 2
Griffin et al. ('The chemistry of photodimers of maleic and fumaric acid derivatives. I. Dimethyl fumarate dimer', J Am Chem Soc (1961), 83: 2725-2728), disclose that dimethyl fumarate degrades in the presence of light to form the photodimer compound tetramethyl cyclobutane-1,2,3,4-tetracarboxylate.
Implementation Method 3
Fumaric acid esters, particularly (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, are prone to photodegradation and oxidative stress, leading to the formation of undesirable impurities when exposed to light or oxidants.
Data Source
AI summary
Pharmaceutical compositions and dosage forms of (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate and/or methyl 4-morpholin-4-ylbutyl (2E)but-2-ene-1,4-dioate, containing low levels of certain impurities are disclosed.